Browse the evidence

Short-term changes in glycaemic parameters were statistically associated with concurrent changes in fat-free mass, muscle strength, and resting metabolic rate.

Monitoring glycaemic parameters may provide insights into metabolic health during weight loss.

Early discontinuation of GLP-1RA therapy is associated with increased risks of coronary artery disease and heart failure.

Clinicians should be aware of the cardiovascular risks when patients discontinue GLP-1RA therapy early.

The addition of testosterone undecanoate improved insulin sensitivity and sexual health compared to tirzepatide monotherapy.

Clinicians should consider the potential benefits of testosterone therapy on metabolic and sexual health in this patient group.

Exercise counseling was documented more frequently among patients with durable weight loss after the last GLP-1RA prescription than among those with weight regain (26.2% vs. 14.7%; P = .04).

Incorporating exercise counseling may enhance weight maintenance outcomes for patients after GLP-1RA therapy.

GLP-1-Rezeptoragonisten, insbesondere Semaglutid, können kardiovaskuläre Ereignisse verhindern.

Semaglutid kann zur Prävention von Herz-Kreislauf-Erkrankungen bei übergewichtigen Patienten eingesetzt werden.

GLP-1 receptor agonist medications have the potential to promote marked weight loss.

Practitioners should consider GLP-1 receptor agonists as a potential option for promoting weight loss.

Obesity should be framed as a chronic, multifactorial disease requiring comprehensive management strategies.

A multidisciplinary approach is essential for effective obesity management.

Emerging agents now include multi-agonists, amylin-based therapies, novel oral compounds, and combination strategies designed to improve not only the magnitude of weight loss, but also its quality, durability, and metabolic consequences.

Practitioners should be aware of new multi-agonist and combination therapies that may offer enhanced benefits for weight loss and metabolic health.

Current data indicate a rapid shift from single-pathway interventions toward multimodal therapeutic strategies in obesity and type 2 diabetes.

Practitioners should consider multimodal approaches as the future direction for treating obesity and type 2 diabetes.

The DRL agent achieved a prediction accuracy of optimal doses of 92%, exceeding traditional models by 15%.

The DRL agent can provide more accurate dosing recommendations compared to traditional methods.

In patients with type 2 diabetes, retatrutide achieved an absolute HbA1c reduction of 2.02%, with 27% of participants reaching normoglycemia.

Retatrutide may improve glycemic control in patients with type 2 diabetes.

An unhealthy lifestyle increases the risk of developing type 2 diabetes more significantly in women than in men.

Healthcare providers should emphasize lifestyle changes, particularly for women, to reduce diabetes risk.

The guidelines focus on cardiovascular risk stratification and management of cardiovascular risk factors in diabetes.

Focus on cardiovascular risk factors is essential for diabetes management.

Quality of life, as measured by the Short Form-36 (SF-36), improved in the experimental group.

Improving quality of life is an important benefit of structured exercise for diabetic patients.

Insulin resistance compromises the body's normal response to insulin, leading to multiple diseases including Type 2 diabetes mellitus.

Practitioners should recognize insulin resistance as a critical factor in managing metabolic diseases.

A new approach via personalized therapy adaptations must be applied to target beneficial effects on complications as well as on body weight management.

Tailoring exercise and nutrition strategies can improve health outcomes for individuals with type 1 diabetes.

Human chorionic gonadotropin (HCG) is effective in treating male infertility due to its luteinizing hormone-like action that triggers testosterone and sperm production.

HCG may be a preferable treatment option for male infertility compared to testosterone replacement therapy.

HCG therapy has positive effects on testosterone production without the side effects on fertility associated with testosterone replacement therapy.

HCG therapy may be recommended for patients concerned about fertility while needing testosterone treatment.

In cancer survivors with obesity, metformin treatment resulted in a significant decrease in IGF-1 levels by 7.2 ng/mL at 6 months.

Metformin may be considered as a treatment option for reducing IGF-1 levels in obese cancer survivors.

New medications for T2DM, such as semaglutide, tirzepatide, and ertugliflozin, have been recently approved.

Healthcare providers should stay informed about newly approved medications for T2DM management.

Gastroenterologists can play an important role in the management of obesity.

Gastroenterologists should be prepared to manage obesity in their patients.

Tirzepatide and cagrilintide-semaglutide are promising agents for adjunctive pharmacological management of weight gain in SMI.

Practitioners should consider these new agents as potential options for managing weight gain in SMI patients.

Low-carb diet (LCD) resulted in lower morning postprandial, noon postprandial, and evening preprandial capillary blood sugar levels.

Implementing a low-carb diet may help improve glycemic control in late pubertal girls with type 1 diabetes.

Glucagon-like 1 receptor antagonists and sodium-glucose co-transporter 2 inhibitors play a role in secondary prevention of atherosclerotic cardiovascular disease.

These agents may be recommended for secondary prevention in diabetic patients with cardiovascular risks.